News room

Latest news and updates

We are engaged in multiple public, private, and academic clinical projects on a daily basis, contributing to the development of innovative medical solutions to those in need. Here, we publish news and highlights of our projects and activities, offering you an up-to-date perspective on our company.

GLORIA aims to prove chronic low dose glucocorticoids are highly effective and safe in elderly patients

The EU Research and Innovation programme HORIZON 2020 has awarded contract worth up to 6 million euro’s to consortium led by Amsterdam Medical Center under grant agreement No 634886. GLORIA aims to prove that the addition of chronic low dose glucocorticoids (GC) to current antirheumatic therapy is highly cost-effective and safe in elderly patients with rheumatoid arthritis (RA). RA is...
Read More

H2020 awards contract to develop a monoclonal antibody against COVID-19

The EU Research and Innovation programme HORIZON 2020 has awarded a contract worth up to 3 million euro’s to a European consortium led by ErasmusMC in collaboration with Harbour Antibodies BV to develop a monoclonal antibody against SARS-CoV 2. This project “MANCO” aims at the development of contributing to the rapid international public health preparedness and response against the novel...
Read More

Update COVID-19: Safeguarding health and safety

As a result of the COVID-19 pandemic, CR2O has adapted its contingency plan aimed to guarantee the safety and well-being of patients, employees, clients and continuity of our services.By following recommendations from Regulatory Authorities (local, EMA and FDA), CR2O continues to focus on patient safety and maintaining compliance with GCP under the current restrictive circumstances.
Read More

ISOLDA aims at the development of improved vaccines against viral infections for older adults

The EU Research and Innovation programme HORIZON 2020 has awarded contract worth up to 6 million euro’s to consortium led by Stiftung Tieraerztliche Hochschule Hannover (TiHo) to develop improved vaccines against viral infections for older adults The average age of citizens of the European Union (EU) is increasing, with currently 20% aged over 65. Ageing is one of the main...
Read More

CEPI awards contract worth up to US$12.5 million to consortium led by Wageningen Bioveterinary Research to develop a human vaccine against Rift Valley fever

Wageningen Bioveterinary Research (WBVR), part of Wageningen University & Research, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new partnering agreement. With support from the European Union’s (EU’s) Horizon 2020 programme, CEPI will provide up to US$12.5 million for vaccine manufacturing, preclinical research, and a phase 1 study to assess the safety, tolerability, and immunogenicity of a...
Read More

Product Development and Clinical Investigation of a MERS-CoV Vaccine based on highly efficient scalable recombinant MVA technology

CEPI awarded a program which is aimed at the manufacturing and stockpiling of clinical supplies of MVA-MERS-S and the concomitant clinical development to a stage where outbreak deployment readiness is demonstrated. As such the project targets the outbreak preparedness for the Middle East Respiratory Syndrome coronavirus (MERS-CoV), which is under WHO public health surveillance. Middle East respiratory syndrome (MERS) is...
Read More